Phase 1 Experience With an Anti-Glycotope Monoclonal Antibody, RAV12, in Recurrent Adenocarcinoma

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-09-2263
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

The Glycotope-Specific RAV12 Monoclonal Antibody Induces Oncosis in Vitro and Has Antitumor Activity Against Gastrointestinal Adenocarcinoma Tumor Xenografts in Vivo

Molecular Cancer Therapeutics
Cancer ResearchOncology
2007English

BIW-8962, an Anti GM2 Ganglioside Monoclonal Antibody, in Previously Treated Advanced/Recurrent Lung Cancer: A Phase I/Ii Study

Journal of Cancer Biology and Therapeutics
2018English

Anti-Pd-1 Monoclonal Antibody MEDI0680 in a Phase I Study of Patients With Advanced Solid Malignancies

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2019English

Long-Term Delivery of an Anti-Siv Monoclonal Antibody With AAV

Frontiers in Immunology
AllergyImmunology
2020English

Triple Combination Immunotherapy With GVAX, Anti-Pd-1 Monoclonal Antibody, and Agonist Anti-Ox40 Monoclonal Antibody Is Highly Effective Against Murine Intracranial Glioma

OncoImmunology
OncologyAllergyImmunology
2019English

A Phase 1 Study of Anti-TGFβ Receptor Type-Ii Monoclonal Antibody LY3022859 in Patients With Advanced Solid Tumors

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2017English

Treatment of Atopic Dermatitis With Tralokinumab, an Anti–IL-13 Monoclonal Antibody

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Phase I Study of Nivolumab, an Anti-Pd-1 Antibody, in Patients With Malignant Solid Tumors

Investigational New Drugs
OncologyPharmacology
2016English

Anti-Tumor Activity of an Anti-Endoglin Monoclonal Antibody Is Enhanced in Immunocompetent Mice

International Journal of Cancer
Cancer ResearchOncology
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy